These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32115314)

  • 41. Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis.
    Goff DC; Zeng B; Ardekani BA; Diminich ED; Tang Y; Fan X; Galatzer-Levy I; Li C; Troxel AB; Wang J
    JAMA Psychiatry; 2018 Apr; 75(4):370-378. PubMed ID: 29466532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The evaluation and treatment of first-episode psychosis.
    Sheitman BB; Lee H; Strous R; Lieberman JA
    Schizophr Bull; 1997; 23(4):653-61. PubMed ID: 9366001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.
    Tek C; Kucukgoncu S; Guloksuz S; Woods SW; Srihari VH; Annamalai A
    Early Interv Psychiatry; 2016 Jun; 10(3):193-202. PubMed ID: 25962699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Perceptions of relapse risks following first-episode psychosis and attitudes towards maintenance medication: a comparison between nursing and social work professionals.
    Chan KK; Chin QP; Tang JY; Longenecker J; Hui CL; Chiu CP; Lam MM; Wong GH; Chen EY
    Early Interv Psychiatry; 2011 Nov; 5(4):324-34. PubMed ID: 21521490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis.
    Berger M; Juster RP; Westphal S; Amminger GP; Bogerts B; Schiltz K; Bahn S; Steiner J; Sarnyai Z
    Psychoneuroendocrinology; 2018 Apr; 90():35-42. PubMed ID: 29427955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of LAI in first episode psychosis: an observational study--clinical reports.
    Cervone A; D'Onghia A; Ferrara M; Massaro CR
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S348-52. PubMed ID: 26417794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: Obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR.
    Stürup AE; Hjorthøj C; Albert N; Dolmer S; Birk M; Ebdrup BH; Eplov LF; Jensen H; Vernal DL; Speyer H; Mors O; Nordentoft M
    Front Psychiatry; 2022; 13():910703. PubMed ID: 35935409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis.
    Faber G; Smid HG; Van Gool AR; Wiersma D; Van Den Bosch RJ
    Eur Psychiatry; 2012 May; 27(4):275-80. PubMed ID: 21561741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reprint of: Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy.
    Wunderink L; van Bebber J; Sytema S; Boonstra N; Meijer RR; Wigman JTW
    Schizophr Res; 2020 Nov; 225():69-76. PubMed ID: 33279373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early identification of treatment non-response in first-episode psychosis.
    Wold KF; Ottesen A; Camilla BF; Johnsen E; Lagerberg TV; Romm KL; Simonsen C; Ueland T; Widing L; Åsbø G; Melle I
    Eur Psychiatry; 2023 Mar; 66(1):e30. PubMed ID: 36915260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of symptom resolution on medication adherence in first episode psychosis.
    Steger KA; Cassidy C; Rabinovitch M; Joober R; Malla A
    Psychiatry Res; 2012 Mar; 196(1):45-51. PubMed ID: 22377571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission.
    Zhang T; Wang J; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Hui L; Li C; Wang J
    Pharmacopsychiatry; 2021 Jan; 54(1):23-30. PubMed ID: 33045753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
    Weller A; Gleeson J; Alvarez-Jimenez M; McGorry P; Nelson B; Allott K; Bendall S; Bartholomeusz C; Koval P; Harrigan S; O'Donoghue B; Fornito A; Pantelis C; Paul Amminger G; Ratheesh A; Polari A; Wood SJ; van der El K; Ellinghaus C; Gates J; O'Connell J; Mueller M; Wunderink L; Killackey E
    Early Interv Psychiatry; 2019 Dec; 13(6):1345-1356. PubMed ID: 30488637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A cross-sectional observational study of healthcare professional views of factors affecting teenage adherence with antipsychotic medication.
    Ramdour S; Duxbury JA; Becket G; Wilson S
    J Psychiatr Ment Health Nurs; 2015 Sep; 22(7):491-501. PubMed ID: 25990303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
    Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Ortiz-García de la Foz V; Vázquez-Bourgon J; González-Pinto A; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2018 Dec; 21(12):1090-1101. PubMed ID: 30215723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis.
    Abdel-Baki A; Medrano S; Maranda C; Ladouceur M; Tahir R; Stip E; Potvin S
    Int Clin Psychopharmacol; 2020 Jul; 35(4):221-228. PubMed ID: 32282448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
    San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
    Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.
    Berger GE; Proffitt TM; McConchie M; Yuen H; Wood SJ; Amminger GP; Brewer W; McGorry PD
    J Clin Psychiatry; 2007 Dec; 68(12):1867-75. PubMed ID: 18162017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [What support of young presenting a first psychotic episode, when schooling is being challenged?].
    Vacheron MN; Veyrat-Masson H; Wehbe E
    Encephale; 2017 Dec; 43(6):570-576. PubMed ID: 29128195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.